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The incidence of type 1 diabetes is increasing world-wide.1 Improved glycemic control during pregnancy has been shown to reduce maternal and neonatal 
complications.2 Continuous glucose monitoring (CGM) is 
an emerging technology intended to replace standard self-
monitoring of blood glucose (SMBG) using a glucometer 
and glucose testing. The most recent Diabetes Canada guide-
line on diabetes and pregnancy recommended the use of 
CGM for pregnant patients with type 1 diabetes to minimize 
maternal and neonatal complications.2 Government funding 
of CGM has recently been suggested for pregnant women 
with type 1 diabetes in Australia, England and Wales.3–5
The Continuous Glucose Monitoring in Women with 
Type 1 Diabetes in Pregnancy Trial (CONCEPTT) was an 
international multicentre, open label, randomized controlled 
trial conducted to determine the effectiveness of CGM com-
pared with SMBG in improving glycemic control during 
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Background: The Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trial (CONCEPTT) found improved 
health outcomes for mothers and their infants among those randomized to self-monitoring of blood glucose (SMBG) with continuous 
glucose monitoring (CGM) compared with SMBG alone. In this study, we evaluated whether CGM or standard SMBG was more or 
less costly from the perspective of a third-party payer. 
Methods: We conducted a posthoc analysis of data from the CONCEPTT trial (Mar. 25, 2013, to Mar. 22, 2016). Health care 
resource data from 215 pregnant women, randomized to CGM or SMBG, were collected from 31 hospitals in 7 countries. We deter-
mined resource costs posthoc based on prices from hospitals in 3 Canadian provinces (Ontario, British Columbia, Alberta). The pri-
mary outcome was the difference between groups in the mean total cost of care for mother and infant dyads, paid by each govern-
ment (i.e., the third-party payer) from randomization to hospital discharge (time horizon). The secondary outcome included CGM and 
SMBG costs not paid by governments (e.g., glucose monitoring devices and supplies).
Results: The mean total cost of care was lower in the CGM group compared with the SMBG group in each province (Ontario: 
$13 270.25 v. $18 465.21, difference in mean total cost [DMT] –$5194.96, 95% confidence interval [CI] –$9841 to –$1395; BC: 
$13 480.57 v. $18 762.17, DMT –$5281.60, 95% CI –$9964 to –$1382; Alberta: $13 294.39 v. $18 674.45, DMT –$5380.06, 
95% CI –$10 216 to –$1490). There was no difference in the secondary outcome.
Interpretation: Government health care costs are lower when CGM is paid by the patient, driven by lower costs from reduced use of 
the neonatal intensive care unit in the CGM group; however, when governments pay for CGM equipment, there is no overall cost dif-
ference between CGM and SMBG. Governments should consider paying for CGM, as it results in improved maternal and neonatal 
outcomes with no added overall cost. Trial registration: ClinicalTrials.gov, no. NCT01788527
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pregnancy in women with type 1 diabetes. The study is 
described elsewhere.6 Briefly, 325 women with type 1 diabetes 
(215 pregnant cohort, 110 planning pregnancy cohort) were 
enrolled in 2 parallel trials between 2013 and 2016 at 31 hospi-
tals in Canada, England, Scotland, Spain, Italy, Ireland and the 
United States. Participants were randomized to receive SMBG 
plus CGM (treatment group) or SMBG alone (control group) 
until birth. The primary outcome for the pregnant cohort, 
change in glycosylated hemoglobin (HbA1c) from randomization 
to 34 weeks’ gestation, improved in the CGM group. Partici-
pants in the CGM group spent more time in the target glucose 
range (3.5–7.8 mmol/L) and less time in the hyperglycemic 
range (> 7.8 mmol/L). The CGM group had improved neonatal 
health outcomes, with fewer infants who were large for gesta-
tional age, fewer admissions to the neonatal intensive care unit 
(NICU) longer than 24 hours, fewer incidences of neonatal 
hypoglycemia and shorter lengths of hospital stay. 
A recent budget impact modelling study using CONCEPTT 
data from the perspective of the National Health Services in 
England determined that routine use of CGM would result 
in substantial cost savings, mainly through reductions in 
NICU admissions and shorter durations of NICU care.7 
However, costs are different in Canada, and no province 
currently pays for CGM supplies. The cost implications of 
using CGM compared with SMBG for health care systems 
funded by the Canadian government are not yet known, and 
thus were evaluated using CONCEPTT data. The aim of 
this study was to determine whether CGM was more or less 
costly than SMBG from the perspective of a third-party 
payer, using CONCEPTT trial data. We evaluated costs 
in the context of 3 Canadian provinces, Ontario, British 
Columbia and Alberta, where the health care system is 
funded and managed by these provincial governments.
Methods
Study design, setting and participants
We conducted a posthoc cost analysis of data from the 
CONCEPTT trial’s pregnant cohort, excluding patients 
without complete outcome data. Patients were randomized 
into the trial from Mar. 25, 2013, to Mar. 22, 2016. We 
sought to determine whether the mean total cost of care per 
mother/infant dyad was more or less costly for those random-
ized to the CGM group compared with the SMBG study 
group. Specifically, we determined the cost of care for preg-
nant CONCEPTT participants if care had been provided in 
Ontario, BC or Alberta, Canada. 
We used a third-party payer perspective as health care in 
Canada is publicly funded through the Ministry of Health 
in each province. In these provincial health care systems, 
patients do not pay for most health care services, but would be 
responsible for paying for CGM devices, CGM sensors, glu-
cometers and glucose testing strips. Collectively, these 3 prov-
inces represent 63% (21.84 million people) of Canada’s popu-
lation8 and 62% of the country’s total public sector health 
expenditure.9 All have similarly structured health care systems. 
Evaluating costs in 3 provinces provides robustness to cost 
comparisons and acts as a sensitivity analysis, and given the 
representativeness of the population covered across these 
provinces, also provides generalizability.
In the CONCEPTT trial, continuous glucose monitors 
and sensors were provided at no cost to participants. Partici-
pants in both CGM and SMBG groups used their own pur-
chased glucometers and glucose testing strips. All interna-
tional centres in the trial were carefully screened and chosen 
by the central coordinating site at Sunnybrook Research Insti-
tute, Toronto, to have facilities, conditions and medical prac-
tices similar to those in Canada. 
Outcomes
The primary outcome was the difference in the mean total 
cost of 18 health care services consumed by mother/infant 
dyads in the CGM group compared with the SMBG group in 
each province. The secondary outcome was the same as the 
primary cost outcome, but included the additional costs of 
CGMs, sensors, glucometers and glucose testing strips, 
assumed to be paid by the government at retail prices. To bet-
ter understand results, we planned an explanatory analysis of 
cost drivers. The time horizon for health outcomes and costs 
was from trial randomization until primary hospital discharge 
for mothers and infants. All costs are in 2013 Canadian dol-
lars, the first year of CONCEPTT trial recruitment.
Data sources
Resource use
In the CONCEPTT trial, we collected health care resource 
utilization data prospectively for mothers and infants from 
randomization until maternal and neonatal hospital discharge 
after birth. We measured 18 health care resources, including 
unscheduled contacts, physician services, hospital ward stays, 
and the number of CGM devices, CGM sensors, glucometers 
and glucose testing strips estimated to have been consumed 
from randomization to delivery. We define unscheduled con-
tacts as all patient visits with the nurse, doctor, research staff 
or CGM helpline that were not already planned in the trial 
schedule of study visits, including clinic visits or appointments 
via phone, email or text.
The total maternal hospital length of stay for delivery was 
available, but not by hospital ward type, which varies sub-
stantially in cost per hour. We estimated duration of use of 
operating rooms and of labour and delivery wards before and 
after the actual birth time using the mean ward duration by 
parity and delivery mode observed in another obstetric 
trial.10 We increased estimates of postnatal labour and deliv-
ery ward duration to 24 hours after delivery, per Canadian 
clinical guidelines for cases where preeclampsia was adjudi-
cated or for cases with hypertensive symptoms during preg-
nancy or after delivery.11,12 We ascribed the time between 
hospital admission and start of labour to the antenatal ward, 
the time from start of labour to estimated labour and deliv-
ery discharge to the labour and delivery ward, and the time 
between estimated discharge to actual hospital discharge to 
the postnatal ward.
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Data from the CONCEPTT trial indicated only that 
infants were admitted to high-level neonatal care. For costing 
purposes, these cases were categorized into level 3 intensive 
(NICU 3) or level 2 intermediate (NICU 2) neonatal ward 
care. Admission to NICU 3 care was attributed to babies with 
reported conditions consistent with provincial admission 
guidelines and billing definitions, including any of the follow-
ing: requiring artificial ventilation, full intensive monitoring 
and parenteral alimentation;13–15 birth at less than 32 weeks, 
birth weight less than 1500 g or positive pressure ventilation; 
or any of 10 possible serious neonatal morbidities requiring 
NICU 3 admission determined from another similar cost 
analysis study (i.e., patent ductus arteriosus, early onset sepsis 
within first 48 hours of life, bronchopulmonary dysplasia, reti-
nopathy of prematurity stage > 2, intraventricular hemor-
rhage, cystic periventricular leukomalacia, hypoxic–ischemic 
encephalopathy, necrotizing enterocolitis, laparotomy or tho-
racotomy).16 Using these parameters, 2 independent neonatol-
ogists, not associated with the CONCEPT trial and masked 
to treatment group and hospital length of stay, adjudicated 
cases admitted to high-level care to either intensive NICU 
level 3 or to NICU level 2.
Costs
We determined the cost of physician services in Ontario, BC 
and Alberta using 2013 provincial government health insur-
ance plan schedules of medical benefits.13–15 All services 
involved a flat or time-dependent fee component, and a pre-
mium depending on time of day and day of the week (i.e., for 
evening, night and weekend calls). Given variation in fees by 
time, an average unit cost per patient was calculated to illus-
trate the unit costs applied in each province (Appendix 2, 
www.cmajopen.ca/content/9/2/E627/suppl/DC1). We deter-
mined costs for time spent in hospital wards using unit costs 
by ward type (antenatal, labour and delivery, operating, post-
natal, NICU 2 and NICU 3) and delivery mode, determined 
for a similar perinatal cost study in 200217 and increased by 
20.5% to 2013 prices using the health care commodity group 
of the Canadian Consumer Price Index.18 Ward unit costs 
were not province specific, but were derived17 from 4 teaching 
and 3 community hospitals in each of the included provinces, 
combined into 1 midpoint unit cost per hour by ward (Appen-
dix 3, www.cmajopen.ca/content/9/2/E627/suppl/DC1). Fur-
ther definitions and assumptions for physician services and 
ward durations are included in Appendix 4, www.cmajopen.
ca/content/9/2/E627/suppl/DC1. Our methods used to derive 
and apply hospital ward unit costs are summarized in Appen-
dix 5, www.cmajopen.ca/content/9/2/E627/suppl/DC1.
We obtained unit costs for CGM devices and CGM sen-
sors from Medtronic Canada and unit costs for glucometers 
and glucose testing strips from Ascensia (formerly Bayer) Dia-
betes Care Canada. Private and retail market costs from 2013 
were available, but insurance or government market costs were 
not; all costs were indicated to be the same in each province 
(Appendix 6, www.cmajopen.ca/content/9/2/E627/suppl/
DC1). We included costs for 1 CGM and 1 glucometer per 
participant in the CGM group, and 1 glucometer per partici-
pant in the SMBG group. The trial protocol indicated the use 
of 1 CGM sensor every 6 days, and 7 glucose testing strips per 
day in both study groups. We estimated total consumption and 
costs of these 2 resources on an intention-to-treat basis, from 
randomization to delivery dates or times for each participant.
Statistical analysis
Costing involved multiplying actual resources consumed by 
each trial participant by their respective unit costs in each 
province to determine the total cost of each of 18 physician 
services and hospital ward stays, and overall total cost for each 
participant. We used an intention-to-treat approach for our 
analysis, whereby mother/infant dyads were included in the 
arm to which they were randomized. Statistical analysis used a 
frequentist approach. We assumed that the mean total costs 
per mother/infant dyad in each arm of the trial were not nor-
mally distributed. 
Using R statistical software version 3.5.1, we estimated the 
standard errors and 95% confidence intervals (CIs) of the dif-
ference in the mean total cost per mother/infant dyad 
between groups using the bias-corrected and accelerated 
(BCA) bootstrap percentile method with 2000 iterations.19 
For each province, we estimated the difference in mean total 
costs and CI for health care services paid by provincial gov-
ernments (primary outcome) and for health care services paid 
by the provincial government, including the cost of CGM 
devices, CGM sensors, glucometers and glucose testing strips 
currently paid by the provincial governments (secondary out-
come). We did not account for any other source of uncer-
tainty than the difference in mean total costs between mother/
infant dyads in each province. We analyzed each province 
separately. All health care resources and unit costs in each 
province were fixed for each mother/infant dyad with no error 
parameters (e.g., physician fee for cesarean delivery, physician 
premium for time of day or week, number of hours on labour 
and delivery ward, number of clinic visits, number of hours in 
NICU level 3). 
To show what was driving costs between the CGM and 
SMBG groups, we determined the absolute difference in 
mean cost between groups for each service and ward, and 
ranked the cost differences in descending order of magnitude. 
For the top unique cost drivers, where parameters were simi-
larly estimated, we tested their significance assuming no dis-
tribution and using an achieved significance level of the BCA 
method, and calculated 95% CIs using bootstrapping with 
2000 iterations. 
We conducted an ad hoc analysis of the cost of all health 
care services paid by provincial governments, including glu-
cometers and testing strips, to estimate the maximum mean 
cost of CGM devices and sensors that could be afforded by 
government while still maintaining a significantly less expen-
sive CGM group cost.
Ethics approval
The CONCEPTT study protocol20 was approved by the 
Health Research Authority, East of England Research Ethics 
Committee (12/EE/0310) for all study sites in the United 
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Kingdom. All other centres obtained ethics approval. Partici-
pants provided written informed consent before enrolment. 
Mount Sinai Hospital Research Ethics Board (12-0037-A) 
approved this posthoc cost analysis.
Results
There were 215 patients in the pregnancy cohort of the 
original trial. We excluded 13 patients without complete 
outcome data for costing from randomization to delivery (9 
cases of spontaneous abortion or termination ≤ 19 weeks and 
4 cases lost to follow-up). Our cost analysis therefore 
included 202 participants, with 100 mother/infant dyads in 
the CGM group and 102 mother/infant dyads in the SMBG 
control group.
Resource use
Service use varied between groups (Table 1). The CGM 
group had more spontaneous vaginal deliveries, fewer elective 
or emergency cesarean deliveries and a shorter maternal hos-
pital length of stay for delivery, including shorter antenatal 
ward duration, compared with the SMBG group. The CGM 
group had 36.7% fewer NICU level 2 admissions, with 65.2% 
less time spent in NICU 2; the CGM group also had 26.7% 
fewer NICU level 3 admissions, with 41.7% less time spent in 
NICU 3. There were 47.3% more unscheduled contacts in 
the CGM group with the nurse, doctor, research staff or 
CGM helpline, mostly for reasons involving the CGM device, 
for both diabetes management and CGM reasons or for other 
unspecified reasons.
Costs
The mean cost in each group represents the total cost 
incurred for services or wards used by all mothers and their 
infants in that group, divided by the total number of women 
in the study group (Appendix 7, www.cmajopen.ca/content/ 
9/2/E627/suppl/DC1). In each province, mean costs were 
about $5300 lower (–$5194.96 in Ontario, –$5281.60 in BC 
and –$5380.06 in Alberta) for the CGM group than the 
SMBG group (Table 2).
When we included costs for CGM devices, CGM sen-
sors, glucometers and glucose testing strips at private market 
rates in the total costs paid for by provincial governments, 
the mean cost of all services and wards was not significantly 
different between CGM and SMBG groups (Table 2).
Cost drivers
Health care resources with the greatest difference in mean 
cost between study groups (i.e., cost drivers) are shown in 
Appendix 8, www.cmajopen.ca/content/9/2/E627/suppl/DC1. 
The total cost of CGM devices, CGM sensors, glucometers 
and glucose testing strips in the CGM group was the biggest 
cost driver when paid by the government. Costs associated 
with the use of the NICU level 2 ward (ranked no. 5 cost 
driver in all provinces) and NICU level 2 physicians (ranked 
no. 11 in all provinces) were also significant cost drivers that 
favoured the lower cost CGM group.
Ad hoc analysis
In our ad hoc analysis, we included the cost of glucometers 
and glucose testing strips for both CGM and SMBG groups, 
but excluded the cost of CGM devices and CGM sensors to 
determine the combined maximum cost of CGM devices and 
CGM sensors to remain less expensive than the SMBG 
group. The maximum mean total cost of CGM devices and 
CGM sensors to remain less expensive than the SMBG group 
for government payers was about $1400 per patient ($1372 in 
Ontario, $1386 in BC and $1473 in Alberta), considering the 
time from randomization to delivery (Table 2). This cost is 
represented by the upper CI level of the difference in the 
mean total cost between groups.
Interpretation
Using data from a large, multicentred randomized controlled 
trial that measured resources prospectively with detailed 
follow-up, we showed that, for government payers, the mean 
costs for overall services and hospital ward use was less expen-
sive in the CGM group than the SMBG group. The upper 
and lower limits of the 95% CIs provide a useful estimation of 
maximum and minimum costs to governments. For example, 
when no CGM devices and consumables are paid by govern-
ments, the overall mean cost savings for the CGM group is 
$5195 in Ontario but could be as much as $9841 or as little as 
$1395. Fewer infants spent time in NICU level 2 in the CGM 
group, significantly lowering overall costs. If provincial gov-
ernments paid for CGM and SMBG devices and consumables 
at the 2013 private market rates, the mean cost of care was 
not different between groups; however, CGM resulted in 
improved health outcomes for mothers and their infants.6 For 
example, the 95% CI showed that the CGM group could save 
the Ontario government as much as $6424 or cost up to 
$1942 more than the SMBG group. Providing CGMs and 
sensors increased costs in the CGM group.
Overall, when governments pay for CGM, mothers and 
infants can reap the important clinical benefits of this technol-
ogy, as observed in the main efficacy trial,6 at no increased 
cost to government. Benefits of CGM observed in the trial 
included improved maternal glucose control, lower total 
length of hospital stay, fewer cesarean births, shorter maternal 
hospital stay for birth, fewer large-for-gestational-age infants, 
less neonatal hypoglycemia, fewer and shorter NICU 2–3 
admissions and lower NICU 2 costs. The CGM group had 
47% more unscheduled contacts, more maternal antenatal 
hospitalizations and more assessments in the obstetrical day 
unit. The higher number of unscheduled contacts in the 
CGM group may reflect initial challenges of integrating 
CGM use into daily diabetes management during early preg-
nancy. With newer, more reliable, user-friendly CGM sen-
sors, these unscheduled contacts may be less frequent. Down-
stream clinical and cost benefits for infants of mothers who 
used CGM and avoided more birth complications and NICU 
admissions were not measured in our posthoc cost analysis, 
but may represent further cost savings to governments.
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Table 1 (part 1 of 2): Health care resources consumed by pregnant women with type 1 diabetes and their infants, 















Antenatal assessments or visits
    Total unscheduled contacts† 1510 96 1025 91
       For diabetes management 844 89 858 87
       For CGM issue 211 63 8 6
       For diabetes and CGM issues 269 42 25 14
       For other reasons not specified 186 51 134 46
    Maternal antenatal hospitalizations 
    ≥ 24 h not for delivery
        No. of admissions 25 22 21 17
        Total length of hospital stay, d 54 42
    Maternal obstetrical day unit
        No. of visits 9 7 8 8
        Total length of visits (assumed 6 h/visit), h 54 48
Delivery
    Pregnancy termination ≥ 20 wk 0 0 1 1
    Stillbirth 0 0 1 1
    Inductions (assumed 1 induction per participant) 49 49 42 42
    Spontaneous vaginal delivery 
    (excludes 1 termination)
28 28 18 18
    Operative vaginal delivery (excluding 1 stillbirth) 9 9 8 8
    Elective or planned cesarean delivery 26 26 30 30
    Emergency or unplanned cesarean delivery 37 37 44 44
Hospital length of stay for delivery







    Total antenatal ward duration‡, h 2306.0 100 4078.1 102
        Participants with hypertensive symptoms or  
        preeclampsia
18 29
    Total labour and delivery ward duration, h 1301.3 100 1600.8 102
    Total operating room ward duration§, h 93.8 72 108.4 84
    Total postpartum ward duration¶, h 7789.6 100 7782.5 102
NICU
Total length of stay in high level NICU for any high 






Total length of stay in high level NICU for physician 
care, d
208 30 430 45
    Adjudicated NICU Level 2 physician care, d 88 19 230 30
    Adjudicated NICU Level 3 physician care, d 120 11 200 15
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Provincial governments in Canada could pay up to $1372 
on CGM devices and sensors and still save money. Providing 
CGMs for pregnant patients with type 1 diabetes would align 
care with the 2018 Diabetes Canada guideline.2 This study 
supports recent suggestions to provincial governments for 
public reimbursement of CGMs for these patients to improve 
maternal and neonatal outcomes.3–5
This posthoc analysis provides clinicians and policy-makers 
with a Canadian comparison of the cost implications of CGM 
and SMBG technologies at private market rates for pregnant 
patients with type 1 diabetes and their infants. A recent bud-
get impact modelling study from the perspective of the 
National Health Services in England determined that the rou-
tine use of CGM would result in substantial cost savings to 
government, mainly through reductions in the number and 
duration of NICU admissions.7 However, we found costs 
were equivalent when Canadian provincial governments paid 
for CGMs. Differences may be because of higher NICU costs 
in the UK or because the UK study used discounted govern-
ment CGM prices, whereas we used retail prices available to 
patients. Evaluating the clinical and cost effectiveness of 
newer, factory-calibrated CGMs that have improved accuracy 
and longer sensor duration, with longer follow-up study peri-
ods to assess any downstream impact of neonatal outcomes on 
health care costs, would be informative.
Limitations
Although we obtained unit costs from 3 Canadian provinces 
with detailed fee structures, resulting in reliable findings 
regarding the cost of care for pregnant patients with type 1 dia-
betes, whether using CGM or SMBG, our approach has some 
inherent limitations. We scaled ward unit costs from 2002 
using health commodity inflation to match 2013 CONCEPTT 
trial data, but scaled costs may not reflect actual ward costs in 
2013. It is possible that our NICU level 3 ward unit cost of 
$107.00 per hour may be lower than that required when caring 
Table 1 (part 2 of 2): Health care resources consumed by pregnant women with type 1 diabetes and their infants, 















CGM and SMBG usage**
No. of days used
    Total, d 18 511.2 100 18 238.6 102
    Per patient, mean ± SD 185.1 ± 17.1 178.8 ± 20.1
No. of patients using Medtronic CGM devices
    Total no. of Medtronic CGM devices 42 42 NA NA
    Medtronic Pump VEO 30 30 NA NA
    Medtronic Veo Kit Pump 10 10 NA NA
    Medtronic Pump 640G 2 2 NA NA
No. of patients using Guardian CGM devices 58 58 NA NA
No. of CGM sensors used (estimated) NA
    Total 3134 100 NA NA
    Per patient, mean ± SD 31.3 ± 2.9 NA NA
Total no. of glucometers used (estimated) 100 100 102 102
No. of SMBG strips used (estimated)
    Total 129 630 100 127 722 102
    Per patient, mean ± SD 1296.3 ± 119.5 1252.2 ± 140.7
Note: CGM = continuous glucose monitoring, NA = not applicable, NICU = neonatal intensive care unit, SD = standard deviation, SMBG = self-monitoring 
blood glucose.
*Unless indicated otherwise.
†Unscheduled contacts refer to patient visits or contacts that were not already planned in the trial schedule of study visits, including clinic visits or 
appointments via phone, email or text, with the nurse, doctor, research staff or CGM helpline. 
‡Participants with hypertensive symptoms or adjudicated preeclampsia had 24 hours added to their labour and delivery ward duration and removed from 
postnatal ward duration.
§Estimated from Early External Cephalic Version 2 trial10 by parity for cesarean delivery and operative vaginal delivery, including for 1 stillbirth and 1 
termination ≥ 20 weeks.
¶Total postpartum ward duration (includes reduction in postnatal ward time given increased labour and delivery ward duration of 24 hours if hypertensive 
symptoms or adjudicated preeclampsia).
**CGM and SMBG usage is estimated from the total number of participant days from randomization to infant birth date. Guardian CGM devices were 
used for non-Medtronic pump users or multiple daily injection users.
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for infants of patients with type 1 diabetes. The resources con-
sumed in the trial may have differed from those which would 
have been consumed in the actual Canadian context, although 
any potential differences cannot be easily determined. None-
theless, we applied estimates to both groups equally. We may 
have mitigated errors by using ward duration estimates from 
another trial, Canadian clinical and provincial admission guide-
lines, billing definitions and masked, independent adjudication 
of high-level neonatal care cases. The CONCEPTT trial was 
powered for clinical rather than cost outcomes, which typically 
require larger sample sizes because of large variances and posi-
tively skewed distributions of costs. Including only Canadian 
patients from the main trial in our study would have resulted in 
an insufficient  sample size for our cost study and may have led 
to subgroup analysis bias of a randomized controlled trial. We 
did not have government prices for CGM devices, which may 
have lowered our overall calculated costs. Future studies should 
use a longer time horizon to establish the cost to health care 
systems incurred after delivery. A societal perspective, includ-
ing costs to the patient, would also be useful to evaluate in the 
design of any future trial of CGM use by pregnant patients 
with type 1 diabetes.
Conclusion
This study shows an approach to analyze costs and clinical 
effectiveness to determine the appropriateness and affordability 
of adopting CGM technology for pregnant patients with type 
1 diabetes. When patients pay for both technologies, CGM is 
less expensive than SMBG to government health care payers, 
and confers substantial clinical benefit for mothers and their 
infants, particularly reduced admissions to NICU level 2 and 
associated costs. If governments pay for up to $1372 for 
CGMs and sensors, they incur no additional overall costs 
compared with SMBG, and improve outcomes for patients 
and their babies. Governments should consider paying for 
CGMs to improve maternal and neonatal outcomes, at no 
added overall cost.  
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Analysis* Province
CGM 
n = 100 mother/infant 
dyads
SMBG 
n = 102 mother/infant 
dyads Difference between CGM and SMBG







Ontario 13 270.25 1122.61 18 465.21 1758.01 –5194.96 2112.07 –9841 to –1395
British 
Columbia
13 480.57 1154.21 18 762.17 1786.67 –5281.60 2154.34 –9964 to –1382







Ontario 17 881.01 1107.80 19 699.65 1752.10 –1818.64 2099.14 –6424 to 1942
British 
Columbia
18 091.32 1139.41 19 996.61 1780.73 –1905.29 2141.33 –6588 to 1957




costs of CGM 
to be < SMBG 
costs 
Ontario 14 546.61 1118.35 19 699.65 1752.10 –5153.04 2102.01 –9801 to –1372
British 
Columbia
14 756.92 1149.96 19 996.61 1780.73 –5239.69 2145.74 –9961 to –1386
Alberta 14 570.75 1136.89 19 908.89 1802.87 –5338.14 2155.59 –10 152 to –1473
Note: BCA = bias-corrected and accelerated, CGM = continuous glucose monitoring, CI = confidence interval, SEM = standard error of the mean, SMBG = 
self-monitoring blood glucose.
*The primary outcome is the total cost of all services, excluding cost of CGM devices, CGM sensors, glucometers and SMBG strips. The secondary outcome is the 
total cost of all services, including cost of CGM devices, CGM sensors, glucometers and SMBG strips. The ad hoc analysis estimates the maximum total cost per 
patient (including cost of CGM devices, CGM sensors, glucometers and SMBG strips) for CGM to remain significantly cheaper than SMBG during type 1 diabetes 
pregnancy. Negative value favours less costly CGM group.
†The 95% CIs were estimated using the BCA method.
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